SeraNovo and Carna Biosciences have announced a second license agreement that will expand the existing partnership to include joint development of an oral formulation of Carna’s kinase inhibitor.
Formulation company, SeraNovo, and biopharmaceutical company, Carna Biosciences, have announced a second license agreement that will expand the existing partnership to include joint development of an oral formulation of Carna’s kinase inhibitor.
According to a May 26, 2020 press release, the terms of the secondary license agreement will see SeraNovo use its Deep Eutectic Solvent (DES) formulation platform to increase the oral bioavailability of one of Carna’s proprietary drugs. The formulation platform from SeraNovo is based on generally recognized as safe (GRAS) excipients that are widely used within the industry for oral administration.
“After our initial license announcement in October 2019, we are pleased to extend our relationship with Carna to include the formulation of another promising active ingredient,” said Niall Hodgins, CEO of SeraNovo in the press release. “This expansion of our partnership with an industry leader is a great development towards wide-spread adoption of our breakthrough formulation technology.”
Source: SeraNovo
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Drug Solutions Podcast: Emerging Methods of Vaccine Administration and Distribution
June 20th 2023Michael Schrader, CEO and co-founder of Vaxess, discusses the latest on vaccine administration and different ways the pharmaceutical industry can distribute these products with Pharmaceutical Technology editor Jill Murphy.
Exosomes Field Advances with Milestones Achieved by EXO Biologics and ExoXpert
December 4th 2024EXO Biologics and ExoXpert, an EXO Biologics subsidiary, have received GMP certification of a European manufacturing facility for exosomes and have successfully loaded mRNA and DNA payloads into GMP-grade exosomes for drug delivery.